In a fast-changing world, with continuing disease pressure and continuous risk of fast emerging diseases, Vaxxinova is committed to providing adequate preventive solutions. Microorganisms do not respect borders and can spread fast, both across geographical borders and across species.
Vaxxinova believes in ‘business without borders’. In other words, we believe that long term local and global professional partnerships between Vaxxinova and veterinarians, animal health professionals and research institutes are the best way to prevent diseases, reduce the use of antibiotics and support performance improvement programs.
The development of vaccines is crucial for our society as vaccines support disease prevention. They make a positive contribution to ‘One Health’, the collaborative effort of multiple disciplines to attain optimal health for people, animals and the environment. Vaccines also help to make the food production more resource efficient and they support the antibiotics reduction.
The Vaxxinova Group was founded in 2010 and currently has operations in 7 countries: Vaxxinova International, the global head quarters which is based in the Netherlands, Biovet (Brazil), IZO (Italy), Vaxxinova GmbH (Germany), Vaxxinova Japan, Vaxxinova Norway and Epitopix, USA.
Vaxxinova is part of the family-owned EW Group. The EW Group specializes in animal genetics, animal nutrition and animal health, operates in over 100 countries and records consistent international growth. Its positive outlook and global orientation have led to an independent and significantly stable position in the market and a steady expansion. As the EW Group is family-owned, which is rare in this sector these days, highly progressive strategies for the future can be pursued, based on long-term investment strategies.